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Background. Localized scleroderma (LSc) is characterized by cutaneous fibrosis and various 
autoantibodies. 
Objective. To determine the presence or levels of antibodies (Abs) against matrix 
metalloproteinase (MMP)-1 and their clinical relevance in LSc.  
Methods. Anti-MMP-1 Ab was examined by ELISA (Enzyme-Linked ImmunoSorbent Assay) 
and immunoblotting using human recombinant MMP-1. MMP-1 collagenase activity was 
determined using biotinylated collagen as substrate and the amount of cleaved biotinylated 
fragments of collagen by MMP-1 was measured by ELISA. 
Results. LSc patients exhibited significantly elevated IgG anti-MMP-1 Ab levels relative to 
normal controls at similar level of patients with systemic sclerosis (SSc). However, IgG 
anti-MMP-1 Ab levels were comparable among the 3 LSc subgroups: morphea, linear 
scleroderma, and generalized morphea. When absorbance values higher than the mean + 2SD of 
normal controls were considered positive, IgG or IgM anti-MMP-1 Ab was found in 46% and 
49% of total LSc patients and SSc patients, respectively. Anti-MMP-1 Ab was detected most 
frequently in morphea patients (60%), followed by linear scleroderma patients (47%) and then 
generalized morphea patients (25%). LSc patients positive for IgG anti-MMP-1 Ab had elevated 
levels of IgG anti-single stranded DNA Ab, IgG anti-nucleosome Ab, and shorter disease 
duration relative to those negative. The presence of anti-MMP-1 Ab in LSc patients was 
confirmed by immunoblotting. IgG isolated from LSc patients’ sera positive for IgG anti-MMP-1 
Ab by ELISA inhibited MMP-1 collagenase activity.  




 Scleroderma, a chronic connective tissue disorder with an autoimmune background, is 
classified into localized scleroderma (LSc) and systemic sclerosis (SSc). LSc exhibits fibrosis 
limited to the skin and the subcutaneous tissues beneath the cutaneous lesions, and differs from 
SSc since LSc is not associated with Raynaud's phenomenon, acrosclerosis, and internal organ 
involvement [1]. Therefore, the prognosis for LSc patients is fairly good; however, the 
disfigurement and deformities of the extremities and face resulting from deep fibrosis 
significantly impair the quality of life [1]. Morphologically, LSc is classified into 3 subsets: 
morphea, linear scleroderma, and generalized morphea [2]. Morphea is usually characterized by 
one or a few circumscribed sclerotic plaques with an ivory-colored center and a surrounding 
violaceous halo. Linear scleroderma appears in a linear, band-like distribution, and often 
involves the muscle and bone underlying the skin lesions. Generalized morphea is a severe form 
of LSc characterized by widespread skin involvement with multiple lesions.  
LSc exhibits autoimmunity as a central feature of the diseases, since antinuclear antibody 
(Ab) is detected in 46-80% of patients [3-5]. These autoantibodies react to various intracellular 
components, including nucleosome, histone, DNA topoisomerase II, and single-stranded DNA 
(ssDNA) [3,4,6-8] and also to some enzymes, such as superoxide dismutase (SOD) [9]. In 
addition, anti-cardiolipin Ab, rheumatoid factor, and lupus erythematosus cell phenomenon have 
been detected in LSc [4,10]. However, it remains unknown whether these autoantibodies directly 
contribute to the disease manifestations of LSc. 
Both SSc and LSc show an abnormal accumulation of extracellular matrix (ECM) 
components, predominantly types I and III collagens [11-13]. The net accumulation of ECM in 
tissue is dependent on the balance between the synthesis and the degradation of ECM 
3 
 
components. The latter process is regulated by matrix metalloproteinases (MMPs), a family of 
zinc-dependent endopeptidases that collectively can digest all ECM components [14,15]. MMP-1 
(interstitial collagenase-1) is able to initiate degradation of interstitial collagen types I, II, and III 
[14]. A recent study has shown that autoantibody against MMP-1 is detected in 49% of patients 
with SSc, especially diffuse cutaneous type of SSc, but not in patients with other autoimmune 
disorders, such as systemic lupus erythematosus and dermatomyositis [16]. However, it remained 
unknown whether anti-MMP-1 Ab was also detected in LSc and whether it was related to some 
clinical manifestations. Therefore, we investigated the presence or levels of anti-MMP-1 Ab, its 
clinical correlation, and its functional significance in LSc patients. 
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MATERIALS AND METHODS 
Serum samples 
Serum samples were obtained from 41 Japanese patients with LSc (11 males and 30 females). 
Patients were classified into the following 3 subgroups as described previously [2]: 12 patients 
with generalized morphea (2 males and 10 females), 19 patients with linear scleroderma (5 males 
and 14 females), and 10 patients with morphea (3 males and 7 females). The age of patients with 
LSc (mean ± SD) was 25.7 ± 17.6 years old (generalized morphea, 22.8 ± 19.8; linear 
scleroderma, 18.6 ± 10.1; and morphea, 42.0 ± 16.2 years old). The disease duration of patients 
with LSc was 4.2 ± 5.8 years (generalized morphea, 3.4 ± 2.8; linear scleroderma, 4.8 ± 7.1; and 
morphea, 4.0 ± 6.3 years). None of LSc patients was treated with oral corticosteroid or other 
immunosuppressive therapy at the evaluation. The number of sclerotic lesions more than 3 cm in 
diameter was counted in each patient with LSc when the serum samples were obtained. The 
sclerotic lesions were morphologically classified into plaque and linear lesions. We divided the 
whole body into the following 7 areas: head and neck; right upper extremity; left upper 
extremity; anterior trunk; posterior trunk; right lower extremity; and left lower extremity, then 
we counted the number of involved areas as described previously [2]. Serum samples from 37 
SSc patients who fulfilled the criteria proposed by the American College of Rheumatology [17] 
were also examined in this study. Thirty-four age- and sex-matched Japanese healthy persons 
were used as normal controls. Fresh venous blood samples were centrifuged shortly after clot 
formation. All samples were stored at -70°C prior to use. The protocol was approved by the 
Kanazawa University Graduate School of Medical Science and Kanazawa University Hospital. 
 
Enzyme-Linked ImmunoSorbent Assay (ELISA) for anti-MMP-1 Ab  
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ELISA was performed as previously described [16]. Briefly, 96-well plates were coated with 
human recombinant MMP-1 (1 μg/ml; Techne Corp., Minneapolis, MN, USA) at 4˚C overnight. 
Wells were blocked with 2% bovine serum albumin and 1% gelatin in Tris-buffered saline (TBS) 
for 1 hour at 37˚C. After washing twice with TBS, serum samples diluted to 1:100 in TBS 
containing 1% bovine serum albumin were added to triplicate wells and incubated for 90 minutes 
at 20˚C. After washing 4 times with TBS containing 0.05% Tween-20, plates were incubated 
with alkaline phosphatase-conjugated goat anti-human IgG or IgM Abs (Cappel, Durham, NC, 
USA) for 1 hour at 20˚C. After washing 4 times with TBS containing 0.05% Tween-20, substrate 
solution containing 0.91 µg/µl p-nitrophenyl phosphate (Sigma-Aldrich Co., St. Louis, MO, 
USA) in diethanolamine buffer (1 M diethanolamine, 0.5 M MgCl2) was added and the optical 
density (OD) of the wells at 405 nm was subsequently determined. Absorbance values greater 
than the mean + 2SD of normal controls were considered positive in this study. 
 
Detection of antihistone Ab, anti-ssDNA Ab, anti-nucleosome Ab, and rheumatoid factor 
ELISA for antihistone and anti-ssDNA Ab was performed as described previously [4]. Briefly, 
96-well microtiter plates were coated with total histones (5 μg/ml; Sigma-Aldrich Co.) at 4°C 
overnight. For anti-ssDNA Ab, wells were pretreated with 0.1% protamine sulfate (grade X; 
Sigma-Aldrich Co.) for 1 hour at 20°C. After rinsing, the plates were coated with calf thymus 
ssDNA (1 μg/ml; Sigma-Aldrich Co.) at 4°C overnight. ELISA was performed as described for 
anti-MMP-1 Ab ELISA. Anti-nucleosome Ab was determined by commercial ELISA kits 
(D-TEK, Mons, Belgium), according to the manufacturer's protocol. Rheumatoid factor was 
measured using a latex agglutination slide test (Eiken, Tokyo, Japan), according to the 





Human recombinant MMP-1 (0.1 μg/lane; Techne Corp.) was subjected to electrophoresis and 
electrotransferred to nitrocellulose sheets. The nitrocellulose strips were incubated overnight 
with serum samples diluted 1:50 and were then incubated for 1.5 hours with alkaline 
phosphatase-conjugated goat anti-human IgG Ab (Cappel). Color was developed using 
5-bromo-4-chloro-3-indrolyl phosphate and nitro blue tetrazolium (Sigma-Aldrich Co.). Ten LSc 
patients positive for IgG anti-MMP-1 Ab by ELISA, 5 patients with LSc negative for IgG 
anti-MMP-1 Ab by ELISA, and 5 healthy individuals were evaluated.  
 
MMP-1 collagenase activity assay 
IgG was purified from serum samples using magnetic beads coated with recombinant Protein G 
covalently coupled to the surface (Dynal Inc., Lake Success, NY, USA). Final IgG concentration 
was measured by spectrophotometer (Gene Quant II, Amarsham Biosciences Inc., Piscataway, 
NJ, USA). MMP-1 collagenase activity was determined by a collagenase activity kit (Chemicon 
International, Inc., Tremecula, CA, USA), according to the manufacture's protocol. Briefly, 4.5 
ng of MMP-1 activated by p-aminophenylmercuric acetate was incubated with 40 μg of purified 
IgG for 20 minutes at 20°C. The enzymatic activity of MMP-1 was measured using biotinylated 
bovine native collagen as substrate. The cleaved biotinylated fragments of collagen by MMP-1 
were transferred to triplicate wells of biotin-binding 96-well microtiter plates and detected by 
streptavidin-peroxidase complex and enzyme substrate. The OD of the wells was subsequently 
determined. MMP-1 that was activated by p-aminophenylmercuric acetate and untreated with 
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IgG served as positive control. Six LSc patients positive for IgG anti-MMP-1 Ab by ELISA and 
6 healthy individuals were assessed.  
 
Statistical analysis  
Statistical analysis was performed using the Mann-Whitney U test for determining the level of 
significance of differences between sample means, Fisher's exact probability test for comparison 
of frequencies, and Bonferroni’s test for multiple comparisons. Spearman's rank correlation 
coefficient was used to examine the relationship between two continuous variables. A p value 




Anti-MMP-1 autoantibody levels by ELISA  
The presence and levels of anti-MMP-1 autoantibodies in serum samples from patients with LSc 
or SSc and normal controls were assessed by ELISA (Figure 1). Patients with LSc exhibited 
significantly elevated IgG anti-MMP-1 Ab levels when compared with normal controls 
(p<0.001). Similarly, IgG anti-MMP-1 Ab levels in SSc patients were significantly higher than 
those found in normal controls (p<0.001). There was no significant difference in IgG 
anti-MMP-1 Ab levels between LSc and SSc patients. Regarding the disease subsets of LSc, IgG 
anti-MMP-1 Ab levels in patients with linear scleroderma and those with morphea were 
significantly higher than those found in normal controls (p<0.01 and p<0.001, respectively), 
while patients with generalized morphea did not exhibit significantly elevated IgG anti-MMP-1 
Ab levels relative to normal controls. However, IgG anti-MMP-1 Ab levels were comparable 
among the 3 subgroups of LSc. By contrast, IgM anti-MMP-1 Ab levels in patients with total 
LSc, generalized morphea, linear scleroderma, morphea, or SSc were not significantly elevated 
compared to normal controls. Thus, IgG but not IgM anti-MMP-1 Ab levels were increased in 
both LSc and SSc at similar level. 
 Absorbance values higher than the mean + 2 SD (1.00 for IgG anti-MMP-1 Ab and 1.04 
for IgM anti-MMP-1 Ab) of the control serum samples were considered positive in this study 
(Figure 1). In total patients with LSc, IgG or IgM anti-MMP-1 Ab was found in 46% (Table 1). 
IgG isotype of this autoantibody (39%) was more frequently detected than IgM isotype (10%). 
Similar positivity was observed in SSc patients (49%). In the subgroups of LSc, IgG or IgM 
anti-MMP-1 Ab was detected most frequently in patients with morphea (60%), followed by 
patients with linear scleroderma (47%) and then patients with generalized morphea (25%). By 
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contrast, IgG or IgM anti-MMP-1 Ab was not detected in any healthy individuals. Thus, IgG 
anti-MMP-1 Ab was detected in LSc and SSc at a similar frequency and the prevalence of IgG 
anti-MMP-1 Ab positivity was the highest in morphea.  
 
Clinical correlation 
Then, we assessed clinical correlation of anti-MMP-1 Ab in LSc patients. LSc patients positive 
for IgG anti-MMP-1 Ab had significantly elevated levels of IgG anti-ssDNA Ab (p<0.05) and 
IgG anti-nucleosome Ab (p<0.05, Table 2). Consistent with this, IgG anti-MMP-1 Ab levels 
correlated positively with levels of IgG anti-ssDNA Ab (r=0.443, p<0.01) and IgG 
anti-nucleosome Ab (r=0.383, p<0.05). Furthermore, the disease duration in LSc patients with 
IgG anti-MMP-1 Ab was significantly shorter relative to those without (p<0.05). However, IgG 
anti-MMP-1 Ab positivity did not correlate with any other clinical parameters. In addition, IgM 
anti-MMP-1 Ab positivity was not related to any clinical parameters (data not shown). Thus, the 
presence of IgG anti-MMP-1 Ab was associated with elevated levels of IgG anti-ssDNA Ab, IgG 
anti-nucleosome Ab, and shorter disease duration in LSc. 
 
Immunoblotting analysis for anti-MMP-1 Ab 
The presence of anti-MMP-1 Ab was further evaluated by immunoblotting analysis using human 
purified MMP-1. Serum samples from LSc patients positive for IgG anti-MMP-1 Ab by ELISA 
exhibited reactivity with MMP-1 (~52 kDa) by immunoblotting (lanes 2-4, Figure 2). By 
contrast, serum samples from LSc patients negative for IgG anti-MMP-1 Ab by ELISA did not 
react with MMP-1 (lane 5). Furthermore, serum samples from healthy individuals did not react 
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with MMP-1 (lane 6). Thus, the presence of anti-MMP-1 autoantibody in patients with LSc was 
confirmed by immunoblotting analysis.  
 
Inhibition of MMP-1 collagenase activity by IgG isolated from serum samples of LSc 
patients which contained IgG anti-MMP-1 Ab 
To determine the functional significance of anti-MMP-1 Ab, it was assessed whether 
anti-MMP-1 Ab was able to inhibit MMP-1 collagenase activity. MMP-1 collagenase activity 
was determined using biotinylated bovine native collagen as substrate. The amount of cleaved 
biotinylated fragments of collagen by MMP-1 was measured by ELISA. Six LSc patients 
positive for IgG anti-MMP-1 Ab by ELISA and 6 healthy individuals were evaluated. Relative 
OD values of IgG anti-MMP-1 Ab by ELISA in 6 LSc patients were 1.228, 1.260, 1.443, 1.468, 
1.552, and 2.292. Furthermore, the presence of IgG MMP-1 Ab was confirmed by 
immunoblotting in all 6 LSc patients. MMP-1 collagenase activity was not inhibited by IgG 
isolated from healthy individuals (Figure 3). By contrast, IgG isolated from serum samples of 
LSc patients positive for IgG anti-MMP-1 Ab by ELISA significantly inhibited MMP-1 
collagenase activity by 84.7% compared with normal control (p<0.05). There was no significant 
correlation between IgG anti-MMP-1 Ab levels by ELISA and the MMP-1 activity inhibition 
levels (r=0.20, p=0.68). Thus, IgG anti-MMP-1 Ab from patients with LSc was able to inhibit 




LSc is characterized by skin fibrosis with autoimmune background. Fibroblasts from the affected 
skin of LSc patients produce increased amount of collagen types I and III and fibronectin [13] 
[12] , which is also observed in fibroblasts derived from the SSc skin [11]. Furthermore, analysis 
using fibroblast cultures derived from different layers of the dermis and subcutaneous tissue has 
shown that the pattern of collagen synthesis in LSc is similar to that of SSc, suggesting that the 
two diseases have a common pathomechanism [18]. In SSc, a previous study has shown that SSc 
fibroblasts exhibit decrease in MMP-1 activity and production compared with normal fibroblasts 
[19]. Likewise, decrease in MMP-1 expression is observed in the LSc fibroblasts [20]. Moreover, 
the efficacy of ultraviolet A phototherapy on skin fibrosis is mainly obtained by increased 
production of MMP-1 and interferon-γ in LSc [21]. Collectively, these findings suggest that 
MMP-1 expression and activity play a role in the development of skin fibrosis in both LSc and 
SSc. In the current study, anti-MMP-1 autoantibody was detected in LSc to a similar level and 
frequency of SSc. The presence of anti-MMP-1 Ab was further confirmed by immunoblotting 
analysis. The finding that anti-MMP-1 Ab levels correlated with levels of anti-ssDNA Ab and 
anti-nucleosome Ab suggests that anti-MMP-1 Ab is produced by autoimmune responses 
common to the production of other autoantibodies in LSc. 
 Both LSc and SSc exhibit autoimmunity as a central feature of the diseases. SSc exhibits 
the production of autoantibodies against various intracellular components, such as DNA 
topoisomerase I, centromere, RNA polymerases, and U3RNP [22]. However, these 
autoantibodies specific to SSc are absent in LSc with few exceptions [4]. Conversely, 
autoantibodies against DNA topoisomerase II and SOD, which are detected in LSc, are not found 
in SSc [8,9]. Thus, although both SSc and LSc show cutaneous fibrosis, autoantibody 
12 
 
specificities associated with these diseases are different. However, LSc and SSc share some 
autoantibody specificities, such as antihistone Ab, anti-ssDNA Ab, and rheumatoid factor. 
Similarly, anti-MMP-1 Ab is detected in both LSc and SSc. Furthermore, anti-MMP-1 Ab is not 
observed in other autoimmune diseases, including systemic lupus erythematosus and 
dermatomyositis, suggesting that anti-MMP-1 Ab is specific to LSc and SSc. Therefore, 
anti-MMP-1 Ab may be an autoantibody closely related to skin fibrosis. 
 A majority of autoantibodies that have been detected in LSc appear to correlate with the 
disease severity of LSc: antihistone Ab, anti-ssDNA Ab, and anti-cardiolipin Ab are most 
frequently positive in generalized morphea, the most severe subset of LSc, compared to linear 
scleroderma and morphea [4,10]. Especially, antihistone Ab correlates with total number of 
lesions and the total area of lesions [2]. On the other hand, autoantibodies against SOD or DNA 
topoisomerase II are found at comparable frequency between the 3 subgroups of LSc [8,9]. By 
contrast, the present study showed that anti-MMP-1 Ab was most frequently detected in morphea 
(60%), followed by linear scleroderma (47%) and then generalized morphea (25%). The reasons 
for this phenomenon remained unknown in this study. However, the early diagnosis of morphea 
is sometime difficult, since early lesions of morphea occasionally show non-specific 
inflammatory change rather than sclerotic change. Therefore, the presence of anti-MMP-1 Ab 
would be helpful for diagnosing early stage of morphea. Moreover, LSc patients with 
anti-MMP-1 Ab exhibited shorter disease duration relative to those without, suggesting that 
anti-MMP-1 Ab is produced in the early phase of LSc. This finding would also help early 
detection of morphea. 
 In SSc, IgG anti-MMP-1 Ab correlates with diffuse cutaneous type of SSc and the extent 
of skin and lung fibrosis [16]. Furthermore, IgG anti-MMP-1 Ab in sera from SSc patients 
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inhibits MMP-1 collagenase activity [16], suggesting that IgG anti-MMP-1 Ab contributes to the 
accumulation of ECM in SSc. Similarly, the current study showed that IgG anti-MMP-1 Ab in 
sera from LSc patients inhibited MMP-1 collagenase activity. However, the presence of IgG 
anti-MMP-1 Ab did not correlate with total number of lesions and the total area of lesions in LSc. 
Unlike SSc, LSc is characterized by the scattered sclerotic lesions that do not involve the whole 
body even if the lesions are multiple. Therefore, it remained unknown why systemic production 
of autoantibodies against MMP-1 in LSc affects only partial body areas, given that the 
autoantibodies can block collagenase activity of MMP-1. It has been reported that various 
physical injury, including trauma, radiation, burn, local corticosteroid injection, surgical 
procedures, immunization, and varicella infection, is a provoking factor in LSc [23,24]. In 
addition, MMP-1 expression is induced in response to exogenous signals, such as various 
cytokines or growth factors, cell-matrix interactions, and cell-cell interactions [14,15]. Indeed, a 
recent study has shown that MMP-1 expression is induced during the process of wound healing 
[25]. Therefore, it may be possible that physical skin injury induces the local expression of 
MMP-1, activity of which may be inhibited by anti-MMP-1 autoantibodies in LSc, suggesting 
that anti-MMP-1 autoantibodies may induce collagen deposition in LSc. However, since 
immunoglobulin deposition was not detected in the lesional dermis of LSc patients positive for 
IgG anti-MMP-1 Ab (data not shown), it remained unknown whether anti-MMP-1 Ab exhibited 
in vivo functional significance in LSc. Nonetheless, the results of this study indicate that 
anti-MMP-1 Ab is a novel autoantibody in LSc. 
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Table 1. Frequency of anti-MMP-1 Ab positivity in LSc, SSc, and normal controlsa. 
 Anti-MMP-1 Ab 
 IgG IgM IgG or IgM 
LSc (n=41) 16 (39) 4 (10) 19 (46) 
  GMb (n=12) 3 (25) 1 (8) 3 (25) 
  Linear Scl. (n=19) 7 (37) 3 (16) 9 (47) 
  Morphea (n=11) 6 (60) 0 (0) 6 (60) 
SSc (n=37) 7 (19) 9 (24) 18 (49) 
Normal (n=34) 0 (0) 0 (0) 0 (0) 
aValues are the number (%) of patients with anti-MMP-1 Ab. IgG and IgM anti-MMP-1 Abs 
were determined by ELISA using anti-human IgG and IgM Abs as secondary Abs, respectively.  
bGM = generalized morphea; Linear Scl. = linear scleroderma. 
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Table 2.  Clinical and serological features of patients with LSc positive for IgG 
anti-MMP-1 Aba. 
 IgG anti-MMP-1 Ab + 
(n=18) 
IgG anti-MMP-1 Ab - 
(n=23) 
Serological   
 Anti-nuclear Ab (%) 10 (56%) 16 (70%) 
 IgG antihistone Ab (OD)b 0.754± 0.254 0.774 ± 0.246 
 IgG anti-ssDNA Ab (OD) 0.683 ± 0.29 * 0.485 ± 0.170 
 IgG anti-nucleosome Ab (OD) 30.2 ± 7.1 * 26.5 ± 5.5 
 Rheumatoid factor (%) 7 (39%) 7 (30%) 
Clinical   
 Sex (male/female) 4/14 7/16 
 Age at onset (years) 26.3 ± 14.6 17.1 ± 18.1 
 Disease duration (years) 2.6 ± 4.4 * 5.1 ± 6.3 
  No. of linear lesions 0.67 ± 0.69 1.22 ± 1.13 
 No. of plaque lesions 2.28 ± 2.85 2.43 ± 2.86 
  Total no. of lesions 2.94 ± 2.86 3.65 ± 3.42 
  No. of involved body areas 1.89 ± 1.37 2.3 ± 1.92 
  Muscle involvement (%) 4 (22%) 5 (22%) 
aValues are mean ± SD, unless otherwise indicated. IgG anti-MMP-1 Ab was determined by 
ELISA using anti-human IgG Abs as secondary Abs. 
bLevels of antihistone Ab, anti-ssDNA Ab, and anti-nucleosome Ab as the relative optical 
density (OD) were determined by specific ELISA. 
16 
 




Figure 1. IgG and IgM anti-MMP-1 Ab levels in serum samples from patients with the 3 
subgroups of LSc. IgG or IgM anti-MMP-1 Ab levels were determined by ELISA using human 
recombinant MMP-1 in patients with generalized morphea (GM), linear scleroderma (LS), or 
morphea (M), those with SSc, and normal controls (CTL). The short bar indicates the mean value 
in each group. A broken line indicates the cut-off value (mean + 2 SD of the control samples).  
 
Figure 2. Immunoblotting analysis of IgG anti-MMP-1 Ab in serum samples from LSc patients. 
Representative immunoblotting of human recombinant MMP-1 with sera from patients positive 
for IgG anti-MMP-1Ab by ELISA, with those negative for it, or normal controls is shown. The 
remaining patients or healthy individuals exhibited similar results. Lane 1, colloidal gold-stained 
MMP-1; lanes 2-4, serum samples from patients with LSc positive for IgG anti-MMP-1 Ab by 
ELISA; lane 5, a serum sample from a LSc patient negative for IgG anti-MMP-1 Ab by ELISA; 
and lane 6, a normal human serum. Markers for molecular weights (kDa) are shown to the left.  
 
Figure 3. Inhibition of MMP-1 collagenase activity by IgG isolated from serum samples that 
contained anti-MMP-1 Ab. IgG was purified from serum samples of LSc patients positive for 
IgG anti-MMP-1 Ab by ELISA and normal control. Purified IgG was incubated with MMP-1 
activated by p-aminophenylmercuricacetate and MMP-1 collagenase activity (activated MMP-1) 
was determined using biotinylated bovine native collagen as substrate. The amount of cleaved 
biotinylated fragments of collagen by MMP-1 was measured by ELISA using a biotin-binding 
microtiter plate. MMP-1 activity is shown as a percentage of p-aminophenylmercuric 
acetate-activated MMP-1 that was defined as 100%. Six LSc patients positive for IgG 
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anti-MMP-1 Ab by ELISA and 6 healthy individuals were assessed. The data are shown as 
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